Since TINRAD has made the aforementioned reagents indigenously, India’s dependence on foreign biotech companies will reduce significantly. Therefore prevent the drain of foreign reserves. The company is using local materials and manpower which will minimize the cost of introduced reagents and more importantly, generate employment. The previously told reagents will be provided to the masses with added value by using proprietary technology. They are cheaper and more stable than their imported alternatives that will enable the users to optimally utilize the resources and achieve greater results in the field.
TINRAD TEAM
Mrs. Manjula Shrivastav, B.Sc.
CEO, Partner
Dr. Tulsidas G. Shrivastav
M.Sc. (Clinical Biochemistry) Ph.D. (Immunodiagnostics) Chief scientist, partner
Mr. Manish Shrivastav
M.Sc. (Biochemistry) Ph.D. (Pursuing in Parasitology) Partner
Ms. Tripti Shrivastav.
BBA Partner
Dr. G. Lakshmi Kumari
M.Sc., Ph.D. Advisor Immunodiagnostic Expert
Dr. M. C. Kapilashrami
MBBS, MD Advisor Public Health Expert
Dr. Rita Singh
M.Sc., Ph.D. Advisor Immunodiagnostic and PCOD Expert
Dr. Anupam Basu
M.Sc., Ph.D. Advisor Immuno and Molecular Diagnostic Expert
Sh.Yashwant
CA, Lawyer
Mr. Sonu
Media Handler